Keymed Bio-B (02162) announced interim results: 截至2026年6月30日止六個月之中期業績公告, net profit attributable to owners RMB12.2bn Title: 截至2026年6月30日止六個月之中期業績公告 Revenue: RMB6.2bn Net profit: RMB12.2bn Profit attributable to owners: RMB12.2bn
